🇺🇸 Bifidobacterium infantis 35624 in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Coordination Abnormal — 1 report (10%)
- Drug Interaction — 1 report (10%)
- Fatigue — 1 report (10%)
- Frequent Bowel Movements — 1 report (10%)
- Headache — 1 report (10%)
- Muscle Injury — 1 report (10%)
- Muscle Spasms — 1 report (10%)
- Pain — 1 report (10%)
- Pollakiuria — 1 report (10%)
- Product Label Issue — 1 report (10%)
Other Gastroenterology approved in United States
Frequently asked questions
Is Bifidobacterium infantis 35624 approved in United States?
Bifidobacterium infantis 35624 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Bifidobacterium infantis 35624 in United States?
Procter and Gamble is the originator. The local marketing authorisation holder may differ — check the official source linked above.